Pharma companies planning to conduct global clinical trials in India often have questions about the approval process and regulatory requirements. In addition, many sponsors seek to understand the advantages of including India in global clinical trials, such as access to a large and diverse patient population, experienced investigators, and cost efficiencies. Before outsourcing clinical trials in India to Contract Research Organizations in India, it is therefore important to have a clear understanding of the regulatory framework and operational landscape in India.
To address these needs, we have compiled a list of common questions frequently raised by industry stakeholders exploring clinical trials in India and clinical research outsourcing India opportunities.
1. Why should pharma companies outsource clinical trials in India?
Clinical trials in India offer pharmaceutical companies access to a large and diverse patient population, skilled investigators, cost-efficient operations, and modern clinical infrastructure. Moreover, several good, high-quality ICH-GCP-compliant CROs in India clinical trials, such as CLINEXEL, have a strong understanding of local clinical trial requirements.
These factors help sponsors accelerate patient recruitment, generate high-quality clinical data, and reduce overall development timelines, making India an attractive destination for global clinical trials in India.
The benefits of outsourcing clinical trials to India include improved operational efficiency, reduced costs, and faster timelines, which are critical for global drug development programs.
2. What makes India a preferred location for global clinical trials?
India’s large pool of treatment-naïve patients, wide range of disease conditions, and growing clinical research expertise make it ideal for conducting global clinical trials in India.
Regulatory reforms such as the New Drugs and Clinical Trials Rules (2019) and subsequent amendments have strengthened regulatory oversight, governance, improved approval timelines, standardized ethical oversight, and transparency. This has significantly enhanced clinical trials in India guidelines and improved sponsor confidence.
CDSCO-FDA compliant CROs like CLINEXEL have experienced team members with the expertise of conducting multiple clinical trials in India for global submissions, including the USFDA, EMA, European, and other agencies.
These factors clearly answer why include India in global clinical trials and demonstrate what makes India suitable for clinical trials.
3. Can I conduct Phase 2 or Phase 3 clinical trials in India?
Yes, you can conduct Phase 2 clinical trials in India and Phase 3 clinical trials in India. The trials are supported by a well-established regulatory and clinical research infrastructure.
India is suitable for Phase 2 and Phase 3 trials because of the following:
- Large and diverse patient population
- Availability of treatment-naïve and treatment-experienced patients
- Disease diversity (communicable and noncommunicable diseases)
- Experienced investigators and research sites
- Cost-efficient trial conduct
- English-speaking investigators and staff
These advantages further strengthen the case for global clinical trials in India and support sponsors asking can clinical trials be conducted in India.
4. What regulatory changes have improved clinical trial conduct in India?
The New Drugs and Clinical Trials Rules (NDCTR) 2019 and subsequent amendments introduced streamlined approval pathways, defined timelines for regulatory review, enhanced safety reporting requirements, Ethics Committee (EC) registration, CRO registration, and robust ethical safeguards.
These reforms have increased transparency and compliance while aligning India more closely with international norms such as ICH-GCP guidelines.
Such developments have significantly improved clinical research regulations in India, making the country more attractive for clinical research outsourcing India and global clinical trials in India.
5. How do clinical trials in India help generate real-world evidence?
Clinical trials in India often support real-world evidence (RWE) generation through post-approval studies, patient registries, and observational research.
With India’s diverse demographic and disease patterns, RWE can strengthen regulatory submissions, inform clinical practice guidelines, and support market access strategies globally.
This is particularly important for sponsors evaluating advantages of clinical trials in India and integrating India into broader global development programs.
6. What are the key advantages of oncology trials in India?
India’s high prevalence of oncology cases, strong network of specialized cancer centers, and experienced oncologists enable efficient oncology clinical trial recruitment and execution.
These oncology clinical trials in India advantages help sponsors generate critical safety and efficacy data for cancer therapies at a faster pace.
Dr. Deepa Arora, CEO of CLINEXEL, in an insightful discussion at the India Oncology Leadership Summit 2026, highlights a critical gap in India’s clinical research landscape, stating that only about 2% of global clinical trials are conducted in India. This limited participation restricts early patient access to innovative cancer therapies.
This further reinforces why conduct clinical trials in India and the need to increase India’s participation in global oncology research.
7. How does patient diversity in India benefit clinical research?
India has a wide disease diversity, including both communicable and noncommunicable conditions. Infectious diseases such as tuberculosis, viral, fungal, and bacterial infections, sexually transmitted diseases, and AIDS remain prevalent.
At the same time, India also has a significant burden of noncommunicable diseases, including cancer, Diabetic Macular oedema, ulcerative colitis, Wet Age-Related Macular Degeneration, and rare disorders.
Disease diversity is also observed across different stages of illness. For example, in oncology, India has a mix of early-stage, treatment-naïve patients identified through screening programs, as well as late-stage, treatment-resistant cases due to delayed diagnosis or lack of access to timely treatment.
This diversity directly improves patient recruitment in India clinical trials, enhances global data relevance, and supports regulatory acceptance. Such diversity supports global drug development and regulatory acceptance of trial results.
8. How do Contract Research Organizations (CROs) add value to clinical trials in India?
Contract Research Organizations in India like CLINEXEL provide specialized services including clinical program management, regulatory strategy and submissions, site management, monitoring, data management, medical writing, and pharmacovigilance.
These clinical trial services in India ensure that sponsors maintain compliance, improve operational efficiency, and generate high-quality data.
Their operational expertise helps sponsors avoid delays, improve data quality, and maintain compliance with regulatory expectations, making them critical partners for CRO for global clinical trials India.
9. How does CLINEXEL support pharmaceutical sponsors in Phase 2 and Phase 3 clinical trials?
CLINEXEL, as a full-service CRO for global clinical trials in India, supports pharmaceutical companies in conducting Phase 2 clinical trials in India and Phase 3 clinical trials in India through comprehensive, end-to-end services:
- Protocol Development and Feasibility Assessment
- Protocol writing or customization for the Indian setting
- Critical review of global protocols to assess feasibility in India
- Regulatory Documentation and Clinical Trial Application
- Preparation of regulatory dossiers
- Submission of clinical trial applications
- Site Selection and Feasibility
- Identification of suitable clinical trial sites
- Site feasibility assessments based on patient availability and infrastructure
- Regulatory and Ethics Committee Approvals
- Coordination for regulatory approvals
- Support for Ethics Committee submissions and approvals
- Site Monitoring
- Clinical trial monitoring to ensure protocol compliance
- Quality oversight and data integrity management
- Local Vendor Selection and Management
- Identification and coordination with local vendors in India
- Support for laboratory, imaging, and other trial-related services
- Local Regulatory Notifications and Safety Reporting
- Local regulatory notifications
- Serious Adverse Event (SAE) reporting and safety management
These services ensure efficient execution of global clinical trials in India with strong regulatory compliance.
10. How does CLINEXEL support pharmaceutical sponsors with regulatory strategy in India?
CLINEXEL provides comprehensive clinical trial consulting in India, including regulatory pathway identification, preparation of the Clinical Trial Application (CTA), liaison with the regulator, submission via the SUGAM portal, and post-submission follow-up to ensure timely approvals.
This makes CLINEXEL a trusted partner for CDSCO regulatory support India.
11. What experience does CLINEXEL have in managing multinational clinical trials?
CLINEXEL has extensive experience managing multinational clinical trials across therapeutic areas by coordinating global regulatory requirements, aligning sites in India with international ICH GCP standards, and ensuring consistent data quality and compliance across geographies.
This expertise strengthens its position as a leading CRO for global clinical trials India.
12. How does CLINEXEL support pharma companies for Translational Materials for Clinical Trials in India?
According to the New Drugs and Clinical Trials Rules 2019, patient-facing documents must be provided in a language understandable to the participant. Ethics Committees also require translated documents for approval.
These translations must:
- Be accurate and culturally appropriate
- Undergo forward and back translation (when required)
- Be approved by Ethics Committees
- Be consistent with the approved English version
CLINEXEL supports sponsors with:
- Translation of patient-facing documents
- Cultural adaptation for Indian populations
- Ethics Committee–ready formatted documents
- Multi-language management for multi-center trials
High-quality translational materials improve compliance, enhance patient understanding, and support successful execution of clinical trials in India.
Conclusion
India has firmly established itself as a strategic destination for global clinical trials in India, offering a powerful combination of patient diversity, regulatory maturity, and operational efficiency. For sponsors evaluating why to conduct clinical trials in India, the advantages extend beyond cost savings to include faster recruitment, high-quality data generation, and global regulatory acceptance.
The evolving clinical trials in India guidelines, supported by NDCTR 2019 and CDSCO oversight, have significantly improved transparency and predictability. This has strengthened India’s position in clinical research outsourcing India and increased confidence among global sponsors.
Additionally, the presence of experienced Contract Research Organizations in India, such as CLINEXEL, ensures that sponsors receive end-to-end support—from regulatory strategy to execution—while maintaining compliance with global standards.
As clinical development becomes more complex and patient-centric, integrating India into global programs is no longer optional but strategic. Sponsors who leverage the advantages of clinical trials in India and collaborate with a reliable CRO for global clinical trials India can accelerate development timelines while ensuring scientific rigor and regulatory compliance.
Frequently Asked Questions (FAQs)
1. Why are global clinical trials conducted in India?
Global clinical trials in India are conducted due to the country’s large patient population, disease diversity, cost efficiency, and availability of experienced investigators and CROs.
2. What are the advantages of clinical trials in India?
The key advantages of clinical trials in India include faster patient recruitment, cost-effective operations, high-quality data generation, and strong regulatory oversight.
3. Can clinical trials be conducted in India for global submissions?
Yes, clinical trials in India are conducted under ICH-GCP-compliant standards and are accepted by global regulatory authorities such as the USFDA and EMA.
4. What makes India suitable for clinical trials?
India is suitable for clinical trials due to its diverse patient population, availability of treatment-naïve patients, strong clinical infrastructure, and improving regulatory framework.
5. What is the role of CROs in global clinical trials in India?
Contract Research Organizations in India provide end-to-end support including regulatory submissions, site management, monitoring, data management, and pharmacovigilance.
6. How does patient recruitment in India benefit clinical trials?
Patient recruitment in India clinical trials is faster due to a large population, high disease prevalence, and access to diverse patient groups across therapeutic areas.
7. What are Phase 2 and Phase 3 clinical trials in India used for?
Phase 2 clinical trials in India evaluate efficacy and dosing, while Phase 3 clinical trials in India confirm safety and effectiveness in larger patient populations.
8. What are the benefits of outsourcing clinical trials to India?
Outsourcing clinical trials in India helps reduce costs, improve timelines, access skilled investigators, and ensure efficient trial execution through experienced CROs.
9. How do oncology clinical trials benefit from India?
Oncology clinical trials in India benefit from high patient availability, specialized cancer centers, and experienced oncologists, enabling faster and more efficient trials.
10. How can a CRO support global clinical trials in India?
A CRO for global clinical trials India supports sponsors with regulatory strategy, CTA submission, site selection, monitoring, safety reporting, and compliance management.
Authors:
Dr. Deepa Arora- CEO- CLINEXEL ( https://www.linkedin.com/in/deepaarora2019/ )
Dr Deepa is a physician with 25+ years of industry experience in leadership positions with pharma in Clinical Development, Medical Research, and Drug Safety departments.
Dr. Deepa led an industry consortium for the implementation of additional risk minimization measures in Europe. Her experience includes the development and execution of clinical development strategy and conducting clinical trials for NCEs, biosimilars, vaccines, complex generics, and repurposed drugs.
Deepa has experience in interacting with various regulators- USFDA, EMA, MHRA, MEB, Health Canada, WHO, TGA for scientific advice, pre-IND meetings, end of phase meetings to discuss clinical development path, clinical trial designs, and post-marketing commitments, including PMS/ Phase IV studies and paediatric investigation plan (PIP).
Dr. Mukesh Kumar– Chief Scientific Officer- CLINEXEL (https://www.linkedin.com/in/dr-mukesh-kumar-m-d-6223457/)
A Physician (MD) with over 25 years of deep expertise in clinical R&D, Dr Kumar’s career is a testament to innovation and excellence in clinical trials, clinical pharmacology, translational research, biopharmaceutics, and clinical development. His contributions have driven global product registrations across regulatory landscapes, including the USFDA, EMA, India, PMDA, and ROW regions.
Dr. Kumar’s illustrious career includes clinical R&D leadership roles at global pharmaceutical giants (Sanofi and Daiichi Sankyo) and large Indian pharma companies (CIPLA, DRL, and LUPIN), where he supported early and late phase clinical trials of innovative products, including repurposed drugs via 505(b)(2) path, complex generics, and biosimilars.
He has played a key role in transforming the R&D business through clinical risk mitigation strategies and high-quality clinical trial executions. With a proven track record of significant contributions in clinical development of over 100 successful product registrations in the U.S. and Europe, he has redefined efficiencies in clinical strategies by implementing cost-effective, innovative clinical trials and pharmacology studies.
As CLINEXEL’s CSO, Dr. Kumar oversees clinical trial operations (Phases I-IV) and clinical program management. His value-added support is available for CLINEXEL-managed clinical trials in optimizing clinical strategies, global clinical development, and driving impactful scientific negotiations for innovative therapies, biosimilars, and complex generics.